StreetInsider.com News Articles

VivoSim makes first commercial sales in China for NAMkind testing

Tue, 21 Jul 2026 08:05:32 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) announced its first commercial sales in China, securing two initial contracts through its local distributor, Tekon, according to a company statement.

The two engagements are with a Shanghai-based oncology biotech and a Chengdu-based pharmaceutical company. Both orders cover gastrointestinal toxicology screening and NAMkind™ GI efficacy profiling for drug candidates in oncology and other disease areas. The company said the contracts represent a meaningful share of its total contracted revenue to date.

VivoSim's NAMkind™ platform uses 3D human organoid models of the liver and intestine, built from primary human donor cells and paired with proprietary AI. The company

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Tue, 21 Jul 2026 08:05:00 -0400

Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced its first commercial sales in China, opening a significant new market for its NAMkind™ testing services. VivoSim delivers both toxicology and efficacy testing built on its 3D human tissue models of the liver and gastrointestinal (GI) tract. The two initial engagements, with a leading Shanghai-based oncology biotech and a large Chengdu-based pharmaceutical

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Tue, 21 Jul 2026 08:05:00 -0400

Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market

Form 8-K VivoSim Labs, INC. For: Jul 16

Fri, 17 Jul 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260717/26782330.html

Form 8-K VivoSim Labs, INC. For: Jul 16

Fri, 17 Jul 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260717/26782330.html

VivoSim Labs prices $4M private placement at $0.85 per share

Thu, 16 Jul 2026 08:30:29 -0400

VivoSim Labs, Inc. (Nasdaq: VIVS) announced a securities purchase agreement with a single healthcare-focused institutional investor for a private placement expected to raise approximately $4.0 million in gross proceeds, before placement agent fees and other offering expenses.

The San Diego-based company agreed to sell 4,705,883 shares of common stock, or common stock equivalents, along with warrants to purchase up to 4,705,883 additional shares, at a combined price of $0.85 per share. The warrants carry an exercise price of $0.85 per share, become exercisable upon receipt of shareholder approval, and expire five years from the initial exercise date.

As part of the transaction,

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Thu, 16 Jul 2026 08:30:00 -0400

SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 4,705,883 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,705,883 shares of common stock at an effective combined price of $0.85 per share and accompanying common warrant for aggregate gross proceeds of

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

Thu, 16 Jul 2026 08:30:00 -0400

Three Biotechs Deliver Catalysts to Watch